APRIL 27-28-MINUTES OF MEETING 
8 
of the Attachment IV-A list but adds additional members. All 
the members of the list "exhibit R-prime (R plasmid carrying 
chrcmoscmal genes) transfer to E. coli K-12 mediated by the 
IncP-1 plasmids." The larger Attachment IV-C list contains 
all the members of the Attachment IV-B list but adds additional 
members. All members of the list "possess R plasmids (including 
R plasmids of the IncP-1 group) transferable to E. coli K-12." 
Dr. Falkow's handout included tables of data and a list of 
references. Drs. Helinski and Spizizen premised to send to 
ORDA a list of published references supporting all the entries 
on the list in Attachments IV-A, IV-B, and IV-C. 
Class v ; 
The RAC adopted exemption (v). 
In considering items to be put under exemption v on the first 
day of the meeting, it was suggested that cloning of Saccharomyces 
cerevisiae DNA in E. coli K-12 be a specific case. Ibis was not 
adopted . 
On the second day of the meeting, a motion passed unanimously 
that "self-cloning" of Saccharomyces cerevisiae be a specific 
case of exemption from the Guidelines under exemption v. 
A composite text indicating all these changes is attached to 
the Minutes as Attachment V. 
D. Dr. Talbot explained that the suggestion was being withdrawn 
and the RAC concurred ( i .e . , there will be no footnote to Pro- 
hibition (i) stating that the prohibition of etiologic agents 
relates only to research in the U.S.). 
E. There was general agreement by the RAC with this concept that 
institutions receiving NIH funding for reccmbinant ENA research 
shall ccmply with the NIH Guidelines for all their recombinant DNA 
research independent of the source of funding. It was discussed 
whether this should be extended even further to all institutions 
that receive any NIH (or perhaps any HEW) funds, i.e., not only 
those that receive NIH funds for reccmbinant ENA research . A 
motion was accepted in principle that all institutions receiving 
NIH funds for recombinant DNA research shall perform all their 
recombinant DNA research, independent of the source of funding, 
in accordance with the standards of the NIH Guidelines. This 
motion distinguishes between following the standards of the 
Guidelines which would be required, and following all the admin- 
istrative procedures of the Guidelines (MUAs reviewed by ORDA, 
etc.) which might not be required. 
[ 524 ] 
